A study published in Journal of the American College of Cardiology evaluated the safety and efficacy of rosuvastatin in preventing contrast-induced acute kidney injury (CI-AKI) in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). This randomized study enrolled 2,998 patients with type-2 DM and concomitant CKD who were undergoing coronary/peripheral arterial angiography with or without percutaneous intervention. These patients were either administered rosuvastatin, 10 mg/day, for 5 days (2 days before, and 3 days after procedure) or standard-of-care. The results revealed that patients in the rosuvastatin group had notably lower incidences of CI-AKI than their controls. Furthermore, during the 30-day follow-up, the rate of worsening heart failure was considerably lower in the patients treated with rosuvastatin than that in the control group. Thus, it was concluded that rosuvastatin significantly reduced the risk of CI-AKI in patients with DM and CKD undergoing arterial contrast medium injection.